Monographie - Folinate calcium

Son güncelleme :
28/04/2024

Folinate calcium

Kimyasal yapı

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Antrex	Finlandiya
Axifolin	Almanya
Bendafolin	İran, Mısır
Biofolic	İtalya
Calcium leucovorin	Türkiye
Calfolex	İtalya
Citofolin	İtalya
Cromaton	Lüksemburg
Dalisol	Hindistan, Kolombiya, Meksika
Degalin	Almanya
Durofolin	Yunanistan
Etamolin	Peru
Eurofolic	Almanya
Fastovorin	Hindistan
Folcasin	Romanya
Folical	Kolombiya
Folidan	İspanya
Folinate de calcium	Fransa
Furoic	İtalya
Innefol	Meksika
Lederfolin	Büyük Britanya, İrlanda, İtalya
Ledervorin calcium	Avustralya, Belçika, Birleşik Arap Emirlikleri, İrlanda, Kolombiya, Lüksemburg, Polonya, Suudi Arabistan
Leucocalcin	Arjantin, Şili
Leucovorin	Almanya, Avusturya, Belçika, Büyük Britanya, İsviçre, Macaristan, Polonya, Slovenya, Türkiye, Yunanistan
Neofolin	Almanya
Novizet	Arjantin
Precileucin	Meksika
Prefolic	İtalya
Refolinon	Büyük Britanya, Yunanistan
Rescuvolin	Almanya, Belçika, Güney Afrika Cumhuriyeti, Hollanda, İsveç, Kolombiya, Lüksemburg, Malezya, Yunanistan
Ribofolin	Almanya, Avusturya, İran
Rontafor	Arjantin
Sanficinate	Yunanistan
Sanifolin	İtalya
Tecnovorin	Kolombiya, Peru
Veravorin	Yunanistan
Xanacanto	Meksika

Kaynaklar : Folinate calcium

	Tip	Yayın
73	Dergi	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Dergi	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
99	Dergi	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150	Dergi	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
155	Dergi	Trissel LA, Martinez JF, Xu QA. Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. Am J Health-Syst Pharm 1995 ; 52: 710-715.
182	Dergi	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Dergi	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Dergi	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Dergi	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
301	Dergi	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
479	Dergi	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	Dergi	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
763	Dergi	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
905	Dergi	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Dergi	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1287	Dergi	Lecompte D, Bousselet M, Gayrard D, Poitou P. Stability study of reconstituted and diluted solutions of calcium folinate. Pharm Ind 1991 ; 53: 90-94.
1410	Dergi	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Dergi	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Dergi	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Dergi	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Dergi	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Dergi	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1754	Dergi	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1914	Laboratuar	Pemetrexed (Alimta®) - Summary of Product Characteristics Eli Lilly 2016
1925	Dergi	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Dergi	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Dergi	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2027	Dergi	Walker SE, Shirley L, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. Can J Hosp Pharm 2005 ; 58: 212-222.
2130	Dergi	Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J. Stabilité du mélange 5-fluoro-uracil-acide fonique : influence des concentrations, du contenant et de la forme de l’acide folinique. Bull Cancer 1999 ; 86, 11: 946-954.
2181	Dergi	Milano G, Renée N. Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique. Bull Cancer 1995 ; 82: 189-195.
2295	Laboratuar	Fosaprepitant (Emend®) - Summary of Product Characteristics Merck Sharp Dohme 2013
2340	Dergi	Walker S.E, Law S, Puodziunas A. Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers Can J Hosp Pharm 2005 ; 58, 4: 212-222.
3474	Laboratuar	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3523	Laboratuar	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3546	Laboratuar	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3619	Laboratuar	Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics Wockhardt 2016
3621	Laboratuar	Phosphate dipotassique - Résumé des caractéristiques du produit Renaudin 2008
3634	Laboratuar	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3694	Dergi	Smith J.A, Morris A, Duafala M.E, Bertino J.R, Markman M, Kleinberg M. Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration. Am J Hosp Pharm 1989 ; 46: 985-989.
3753	Laboratuar	Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics Cubist Pharmaceuticals 2014
3838	Laboratuar	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3933	Laboratuar	Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit Teva Laboratoire 2015
4154	Laboratuar	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4720	Laboratuar	Nuzyra (amadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021. Paratek Pharmaceuticals 2021

Mentions Légales